Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD)
This trialstudies the effects of medication on cognition in kids & teens with intellectual disability and ADHD. 68 participants will receive drug or placebo in a 1:1 ratio, monitored and assessed for 5 weeks.
- Attention Deficit Hyperactivity Disorder (ADHD)
- Fragile X Syndrome
- Intellectual Disability
- Down Syndrome
1 Primary · 2 Secondary · Reporting Duration: 11 weeks
2 Treatment Groups
1 of 2
1 of 2
68 Total Participants · 2 Treatment Groups
Primary Treatment: Methylphenidate · Has Placebo Group · Phase 1
Who is running the clinical trial?
Age 6 - 17 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are eligible for this clinical trial?
"Yes, the research hosted on clinicaltrials.gov reveals that this medical experiment is currently searching for participants. This investigation was first posted in February of 2023 and has been recently updated as October 24th 2022. There are 68 slots available across 3 different sites." - Anonymous Online Contributor
Are recruitment efforts for this experiment still ongoing?
"The details on clinicaltrials.gov indicate that this trial is still open for enrolment, with the initial posting occurring February 1st 2023 and the most recent update issued October 24th 2022." - Anonymous Online Contributor
What potential risks accompany taking Methylphenidate?
"The safety of Methylphenidate is judged to be a 1 due to its Phase 1 status, indicating that there have been few studies conducted on the medication's efficacy and safety." - Anonymous Online Contributor
Is there an age restriction to qualify for this clinical investigation?
"This trial is seeking participants who are within the juvenile age range, being over 6 and under 17 years of age." - Anonymous Online Contributor
Who has the capacity to be included in this experiment?
"This medical trial is currently enrolling 68 minors (age 6-17) with intellectual disability and ADHD. All participants must be capable of valid NIHTB-CB tests, have an IQ between 50-80, a mental age score of 4 or above on the Stanford Binet test, and provide diagnosis for both conditions." - Anonymous Online Contributor